secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015255
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Q2 net loss $185.8M; exa-cel on track for EU/UK regulatory filing by year-end
--------------------------------------------------------------------------------

- Net loss of $185.8M in Q2 2022 vs net income of $759.2M in Q2 2021; revenue fell to $0.2M from $900.2M due to prior-year Vertex upfront.
- Cash & equivalents $2.07B as of June 30, 2022 (down from $2.38B at Dec 31, 2021); cash used for R&D and pre-commercial costs.
- exa-cel: CLIMB-111/121 fully enrolled; regulatory submissions for SCD & TDT planned in Europe/UK by end of 2022; FDA discussions ongoing.
- Enrollment continuing for CTX110 (CD19+), CTX130 (CD70) in solid/hematologic tumors; CTX110 data expected in 2022.
- Next-gen CAR-T INDs (CTX131, CTX112) expected by year-end; VCTX211 CTA for T1D in H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022015255/0000950170-22-015255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017022015255/crsp-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer